Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.37 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.37 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.37 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.37 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770695 | 0.86 | CCNB2 (0.45) | PDE2ARIPK1 | |
| SCHEMBL12065644 | 0.83 | MLKL (0.52) | PDE2ACBFBSCN10ARUNX1 | |
| SCHEMBL12065648 | 0.81 | PDE10A (0.42) | PDE2ANPY5RCBFBRUNX1 | |
| SCHEMBL12065643 | 0.76 | SCN10A (0.46) | PDE2ASCN10ATRPV1RUNX1 | |
| SCHEMBL14762782 | 0.76 | SCN10A (0.43) | PDE2ASCN10ATRPV1 | |
| SCHEMBL12065627 | 0.75 | MEN1 (0.46) | PDE2ASCN10A | |
| SCHEMBL31661032 | 0.71 | GRM4 (0.34) | PDE2ARIPK1 | |
| SCHEMBL12065635 | 0.71 | MLKL (0.68) | CBFBSCN10ATRPV1RUNX1 | |
| SCHEMBL12066026 | 0.69 | PDE2A (0.37) | PDE2ASCN10A | |
| SCHEMBL1106425 | 0.69 | HSD17B10 (0.46) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | claimed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | PDE2A 1306/4885NPY5R 965/4885ENPP2 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.